Presentation is loading. Please wait.

Presentation is loading. Please wait.

CoPrincipal Investigators

Published by珍 经 Modified over 5 years ago

Similar presentations

Presentation on theme: "CoPrincipal Investigators"— Presentation transcript:

1 CoPrincipal Investigators
SARC013/NO SARC Global Collaboration: Phase 3 trial of R1507 in combination with cyclophosphamide/topotecan versus cyclophosphamide/topotecan alone for treatment of first recurrence Ewing sarcoma CoPrincipal Investigators Herbert Juergens Paul Meyers Shreyaskumar Patel

2 SARC013/NO21158 Open label, randomized, multicenter Phase 3 study
Comparing Regimen 1 and Regimen 2 Regimen 1: R1507 in combination with cyclophosphamide/topotecan versus Regimen 2: cyclophosphamide/topotecan alone (crossover to single agent R1507)

3 SARC013/NO21158 Primary Objective Secondary Objectives
Determine overall progression free survival of Regimen 1 versus Regimen 2 Secondary Objectives Determine overall objective response rate, response duration, and overall survival Determine rate of PFS at 12 weeks Define tolerability and adverse event profile Determine response rate and PFS in patients who crossover from Regimen 2 to single agent R1507

4 SARC013/NO21158 Exploratory Objective
Explore patterns of protein expression in serum and tumor tissues as predictors of response, survival, and progression free survival in patients treated with R1507

5 SARC013/NO21158 Target population Patients age 2 or older
First recurrence Ewing sarcoma who have received one prior treatment regimen Accrue 140 evaluable patients per arm

6 SARC013/NO21158 Eligibility criteria
Histologically confirmed Ewing sarcoma (central review) Age > 2 years Performance status Karnofsky or Lansky 70% Measurable disease Adequate organ function HbA1c < 7%

7 SARC013/NO21158 Exclusion criteria
Clinically significant unrelated systemic illness Prior exposure to topotecan or irinotecan Prior treatment with IGF-1R inhibitor Pregnant Active CNS disease

8 SARC013/NO21158 Early safety review Accrual of 20 patients
10 in each of the treatment groups At least 4 patients per group age > 21 years Data safety monitoring board to review cumulative toxicity data Continue study Modify protocol Terminate study

9 SARC013/NO21158 Response Evaluation
Evaluations every 6 weeks for the first 36 weeks, then every 12 weeks Response and progression by World Health Organization criteria

10 SARC013/NO21158 Local Therapy Following disease restaging at week 12 patients may receive radiation and/or surgery for local control as appropriate Patients requiring local interventions prior to week 12 will be considered as progressive disease

11 SARC013/NO21158 Protocol in development Anticipated activation
Protocol steering committee Anticipated activation Spring 2009

Download ppt "CoPrincipal Investigators"

Similar presentations

SARC023 Phase I/II trial of ganetespib, an heat shock protein 90 inhibitor in combination with the mTOR inhibitor sirolimus for patients with unresectable.

SARC023 Phase I/II trial of ganetespib, an heat shock protein 90 inhibitor in combination with the mTOR inhibitor sirolimus for patients with unresectable.
Modified Megestrol The Clinical Trials by : Carolina R. Akib

Modified Megestrol The Clinical Trials by : Carolina R. Akib
A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing-like sarcoma Coordinating Investigator:

A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing-like sarcoma Coordinating Investigator:
Introduction  Soft Tissue Sarcoma (STS) are a group of highly chemotherapy resistant tumors  Doxorubicin is the only APPROVED 1 st line chemotherapy.

Introduction  Soft Tissue Sarcoma (STS) are a group of highly chemotherapy resistant tumors  Doxorubicin is the only APPROVED 1 st line chemotherapy.
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.

EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.
CTEP IND LOI Review and Approval Process. Study Proposals Letter of Intent May be sent in response to solicitation May be sent by investigator with interesting.

CTEP IND LOI Review and Approval Process. Study Proposals Letter of Intent May be sent in response to solicitation May be sent by investigator with interesting.
SARC015: Phase II study of R1507 in wild-type GIST Margaret von Mehren, Fox Chase Cancer Center Katie Janeway, Dana Farber Cancer Institute.

SARC015: Phase II study of R1507 in wild-type GIST Margaret von Mehren, Fox Chase Cancer Center Katie Janeway, Dana Farber Cancer Institute.
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide in Patients with Previously Treated,

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide in Patients with Previously Treated,
1 SNDA 20-509 Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.

1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.

SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.

BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
MABEL – a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan H Wilke, R Glynne-Jones, J Thaler,

MABEL – a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan H Wilke, R Glynne-Jones, J Thaler,
A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.

A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.
SNDA 20-726 Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.

SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.
A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.
P.A. Tang 1, S. J. Cohen 1, G. Bjarnason 1, C. Kollmannsberger 1, K. Virik 1, M. J. MacKenzie 1, J. Brown 1, L. Wang 1, A. Chen 2, M. J. Moore 1 1 Princess.

P.A. Tang 1, S. J. Cohen 1, G. Bjarnason 1, C. Kollmannsberger 1, K. Virik 1, M. J. MacKenzie 1, J. Brown 1, L. Wang 1, A. Chen 2, M. J. Moore 1 1 Princess.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Agency Review of sNDA 50-718 SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.

Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.

Similar presentations

Ads by Google